MedTrace Logo

Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis

NCT05119452 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2021-11-15

No results posted yet for this study

Summary

To evaluate whether stringent follow-up consisting of combined laboratory and ultrasound surveillance is superior to clinical monitoring alone to maintain clinical remission in rheumatoid arthritis.

Conditions

Interventions

OTHER

Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)

The biological/targeted synthetic disease modifying anti-rheumatic drug will be discontinued in both arms at baseline

Sponsors & Collaborators

  • Medical University of Graz

    collaborator OTHER

  • Medical University Innsbruck

    collaborator OTHER

  • Hospital Hietzing

    collaborator OTHER

  • Krankenhaus Bruneck

    collaborator OTHER

  • Medical University of Vienna

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-31
Primary Completion
2024-09-30
Completion
2024-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05119452 on ClinicalTrials.gov